^
Association details:
| Biomarker: | PIK3CA mutation |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
1O - Neratinib + capecitabine vs lapatinib + capecitabine in HER2+ metastatic breast cancer previously treated with ≥2 HER2-directed regimens: Exploratory biomarker analyses from phase III NALA trial
Published date:
05/23/2020
Excerpt:
PIK3CA and ERBB2 mutations were detected at incidences of 35.0% (148/420) and 6.2% (26/420), respectively. PIK3CA mutations were associated with decreased PFS (wt vs mut: HR=0.81; 95% CI 0.64–1.02; p=0.077)….PIK3CA mutations associate with decreased PFS for pts enrolled in the NALA trial. Higher HER2 protein expression associates with increased PFS in the overall study population, and a greater benefit from N+C vs. L+C.
Secondary therapy:
capecitabine
Trial ID:
Source:
Title:
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Published date:
08/01/2016
Excerpt:
PIK3CA mutations were associated with shorter median PFS (mutant vs. wild type: 4.3 vs. 6.4 months) and OS (17.3 vs. 27.8 months) in capecitabine plus lapatinib–treated patients, but not in T-DM1-treated patients (PFS, 10.9 vs. 9.8 months; OS, not reached in mutant or wild type).
Secondary therapy:
capecitabine
DOI:
10.1158/1078-0432.CCR-15-2499
Trial ID:
